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Abstract The binding of polyamidoamine (PAMAM) den-
drimer or Tat peptide to trans-acting responsive element
(TAR) RNA has been studied using microgravimetric quartz
crystal microbalance (QCM). Experimental results showed
that PAMAM dendrimer could form complexes with TAR
RNA. Especially, PAMAM dendrimer could disrupt the inter-
action of Tat peptide with TAR RNA, which is essential for
HIV-1 virus replication, suggesting that QCM is a powerful
tool for studying the binding processes of Tat peptide^TAR
RNA and drug^TAR RNA and has great signi¢cance for the
design of new drugs. An equation to measure the binding ability
between TAR RNA and other species has been proposed.
- 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Arya et al. [1] reported that the human immunode¢ciency
virus type 1 (HIV-1) Tat protein is essential for HIV replica-
tion, which viewpoint was further proved by Dayton et al. [2].
Tat is introduced to the transcription complex following bind-
ing to an RNA stem-loop structure, the trans-acting respon-
sive element (TAR), located at the 5P end of the viral mRNA
[3^6]. TAR RNA has a stable hairpin structure [7]. Recent
experiments have demonstrated that Tat binds to TAR RNA
in the region of a three base bulge and those adjacent Wat-
son^Crick base pairs and the positions of surrounding phos-
phate groups [8^10]. Tat protein is 86^101 amino acids long,
contains the N-terminal activation domain and the C-terminal
RNA binding domain. The binding a⁄nity and characteristics
of Tat peptides, consisting of a highly basic domain encom-
passing amino acid residues 47^58, are remarkably similar to
those of the full-length protein [11,12].
The interaction of Tat with TAR is crucial for the produc-
tion of full-length viral transcripts and the proliferation of the
virus. Therefore, ¢nding drugs that bind TAR RNA, and
block binding by Tat, would provide a strategy for inhibiting
HIV replication. A number of recent studies have shown that
aminoglycoside antibiotics [13,14], TAR RNA decoys [15,16],
TAR ribozyme [17] and Tat peptide analogs [18,19] could
block Tat^TAR binding. In addition, our previous studies
[20] have also shown that poly(allylamine hydrochloride)
(PAH) could disrupt the Tat^TAR interaction. As we know,
PAH belongs to the traditional linear polymers. Compared
with traditional linear polymers, polyamidoamine (PAMAM)
dendrimers are a relatively new and exciting class of nano-
scopic, spherical, mono-dispersed, highly branched three-di-
mensional polymers. More importantly, PAMAM dendrimers
have been determined to be non-immunogenic and exhibit low
mammalian toxicity [21]. These characteristics, along with
water solubility, are some of the features that make them
attractive for biological and drug-delivery applications [22].
In addition, PAMAM dendrimers could form complexes
with DNA through electrostatic interactions between nega-
tively charged phosphate groups of the nucleic acid and pro-
tonated (positively charged) primary amino groups on the
dendrimer surface [23]. Therefore PAMAM dendrimers are
promising inhibitors, through binding strongly with the phos-
phate groups on TAR RNA preventing Tat binding to TAR
RNA.
Gel shift and ¢lter binding assays are common approaches
for the study of protein^nucleic acid interaction [6,24]. The
microgravimetric quartz crystal microbalances (QCMs) are
suitable transducers for chemical and biochemical sensing in
general. They have been used to monitor DNA^protein for-
mation in real time [25]. In the present paper, we report the
application of QCM to the study of TAR RNA^protein and
TAR RNA^PAMAM dendrimer interaction at interfaces.
2. Materials and methods
2.1. Materials
Neutravidin was obtained from Pierce (Rockford, IL, USA). Third-
generation (G3) PAMAM dendrimers (Fig. 1) were purchased from
Aldrich. They were used without further puri¢cation. Tris^HCl bu¡er
(10 mM Tris^HCl, 70 mM NaCl, 0.2 mM EDTA, pH 7.4) was used to
prepare solutions. They and all other chemicals were analytical re-
agent grade.
The biotinylated TAR RNA (biotin-5P-GCCAGAUCUGAGCC-
UGGGAGCUCUCUGGC-3P) (Fig. 2) was purchased from TaKaRa
Biotechnology (Dalian, China). The Tat peptide, Gly Arg Lys Lys
Arg Arg Gln Arg Arg Arg (Fig. 3), was received from Shanghai
Sangon Biological Engineering Technology and Service (Shanghai,
China). They were used as received.
2.2. Gravimetric measurements with QCM
AT-cut quartz crystals with a fundamental frequency of 9 MHz
were purchased from Seiko EGpG (Tokyo, Japan). These crystals
were coated with thin gold layers on both sides (e¡ective surface
area, 0.196 cm2). Before use, the Au surface of the quartz resonator
was cleaned with piranha solution (H2SO4 :30% H2O2 =3:1) for 2 min.
They were then thoroughly washed with double distilled water and
used immediately afterwards. The resonator was immersed in a 1 mg/
ml neutravidin solution for 30 min to obtain the neutravidin layer. It
was rinsed with bu¡er and water. Then it was immersed in a
1.0U1036 M biotin-TAR RNA for 60 min, and rinsed with bu¡er
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and water similarly. Then it was immersed in a PAMAM dendrimer
(Fig. 4A) or Tat peptide (Fig. 4B) solution for 60 min. After rinsing, it
was immersed in a PAMAM or Tat peptide solution for 60 min. All
experiments were carried out at room temperature (22R 1‡C).
2.3. Atomic force microscope (AFM) measurements
The surface morphology of the thin ¢lm was studied by tapping
mode AFM (Nanoscope III, Digital Instruments, USA).
3. Results
3.1. AFM analysis
Mica was chosen as substrate because of its atomically £at
surface over a large area. A drop of PAMAM dendrimer so-
lution spreads rapidly across the mica surface in a thin layer
because of the high hydrophilicity of the mica surface when it
is deposited on a freshly cleaved mica surface. Cationic PA-
MAM dendrimers can be easily adsorbed on the negatively
charged mica surface by electrostatic attractive force. It can be
seen from Fig. 5A that PAMAM dendrimers are uniformly
adsorbed on mica. Comparing Fig. 5B to Fig. 5A, it can be
Fig. 1. Chemical structure of G3 PAMAM dendrimers.
Fig. 2. Secondary structure of biotinylated HIV-1 TAR RNA. Fig. 3. Primary structure of HIV-1 Tat peptide.
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easily seen that TAR RNA can form complexes with PA-
MAM dendrimers.
3.2. QCM analysis
Using the highly speci¢c and extremely strong non-covalent
binding of biotin to the deglycoprotein neutravidin
(KD = 10315 M) [26], biotin^TAR RNA was immobilized
onto the neutravidin-modi¢ed QCM surfaces.
As shown in Fig. 6A, an increase in response is observed
when the concentration of PAMAM dendrimer is increased.
No obvious mass change was observed when only neutravidin
was present on the sensor surface (Fig. 7B), suggesting that
PAMAM dendrimers interact speci¢cally with TAR RNA.
Fig. 6B shows that an increase of Tat peptide concentration
resulted in increased mass change, subsequent leveling o¡ is
achieved as the surface saturates. Fig. 7D shows that Tat
peptide could not be attached to the neutravidin layer, indi-
cating that Tat peptide interacted speci¢cally with TAR RNA.
As seen from Fig. 7A, no obvious mass shift is observed
when Tat peptide binds to TAR^PAMAM complex, implying
that the interaction of Tat with TAR is blocked by PAMAM
dendrimer. On the other hand, signi¢cant mass change is ob-
tained when PAMAM dendrimer binds to Tat^TAR complex
(Fig. 7C), indicating that a ternary complex of TAR^Tat^
PAMAM dendrimer is formed, in agreement with [27].
4. Discussion
The interactions between Tat and TAR are critical for virus
replication. Furthermore, RNA is the genetic material of HIV,
indicating that targeting of speci¢c RNA structure will pro-
vide numerous opportunities for the design of novel anti-viral
drugs. Indeed, various types of cationic molecules, including
aminoglycoside antibiotics [13,14], heterocyclic molecules
[28,29], polyamine-acridine-based compounds [30] and PAH
[20], have been employed as HIV inhibitors. These diverse
materials have in common the ability to bind TAR RNA
via charge-based interactions.
PAMAM dendrimers are an interesting new class of highly
de¢ned, spherical, cationic polymer [31]. The unique structur-
al features and properties of PAMAM dendrimers make them
ideally suited both for a wide range of biomedical applications
and as platforms for biomimetic chemistry. Because of the
high number of positive charges on their surfaces, PAMAM
dendrimers form a stable electrostatic complex with negatively
charged nucleic acids in bu¡er at physiological pH. Our stud-
ies indicated that PAMAM dendrimers could form a complex
with TAR RNA and e¡ectively inhibit the binding of Tat to
TAR RNA, suggesting that binding of PAMAM dendrimers
to TAR RNA changes the molecular structure of TAR RNA.
And the structural transition induced by PAMAM dendrimers
Fig. 4. Schematic illustration of the recognition processes.
Fig. 5. AFM images of G3 PAMAM dendrimer (A) and G3 PAMAM dendrimer^TAR RNA complex (B) on mica.
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is apparently incompatible with the binding of Tat. We have
not studied speci¢c binding. We think it will be a good subject
for our future studies. Just as reported by Du et al. [33],
compounds capable of locking TAR into a stable conforma-
tion, regardless of similarity to the Tat binding conformation,
should prove useful in inhibiting HIV-1 viral replication.
Therefore PAMAM dendrimers are potent inhibitors for
HIV-1 viral replication. Furthermore, the interaction between
¢xed TAR RNA and the species in solution could be depicted
by an equation similar to the Langmuir adsorption isotherm.
That is
y ¼ yr CðKD þ CÞ ð1Þ
where y is the binding amount (mol) of Tat or PAMAM to
TAR (capacity for TAR^Tat or TAR^PAMAM binding), yr
is the maximum amount of Tat or PAMAM binding (mol) to
TAR, which should be equal to the amount of TAR if they
are in a 1:1 combination, KD is the dissociation constant of
the PAMAM^TAR or Tat^TAR complex, and C is the con-
centration of PAMAM or Tat in solution. Calculating results
shows that the combination coe⁄cient (K31D ) of Tat^TAR is
1.1U105 M31, which compares well with the value reported in
the literature [32], although the physical background and cal-
culated equation are di¡erent (TAR in our case is ¢xed on the
solid substrate), whereas the combination coe⁄cient of PA-
MAM^TAR is 1.8U107 M31, 100 times higher than that of
Tat^TAR, suggesting that PAMAM dendrimer has much
stronger a⁄nity for TAR than Tat does.
Comparing the present results with those of our previous
studies [20], we found that the concentration of inhibitor de-
creased by one order. That is to say, the binding of Tat pep-
tide to TAR RNA could be blocked by 3.0U1037 M PA-
MAM dendrimer or 2.0U1036 M PAH [20], which may be
due to spherical PAMAM dendrimers having a lower steric
e¡ect than linear PAH when they bind to TAR RNA.
In conclusion, this paper demonstrates that PAMAM den-
drimers could form a stable complex with TAR RNA. PA-
MAM dendrimer has a stronger a⁄nity for TAR RNA than
Tat does. PAMAM dendrimer could e¡ectively disrupt Tat^
TAR RNA interaction. The proposed methods and the
unique structural features and properties of PAMAM den-
drimers have great signi¢cance for the design of new drugs.
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